川发龙蟒(002312) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period reached ¥1,318,826,255.41, representing a significant increase of 576.04% year-on-year[8]. - Net profit attributable to shareholders of the listed company surged by 1,872.52% to ¥535,974,432.55[8]. - The net profit after deducting non-recurring gains and losses was ¥97,815,149.88, an increase of 371.36% compared to the same period last year[8]. - Basic and diluted earnings per share were both ¥0.4040, up 1,928.05% from the previous year[8]. - Total revenue for the current period reached ¥1,318,826,255.41, a significant increase from ¥195,079,967.30 in the previous period, indicating a growth of approximately 576.5%[86]. - Net profit for the period reached CNY 535,730,319.82, a significant increase from a net loss of CNY 30,237,908.44 in the previous period[93]. - The total comprehensive income for the period was CNY 535,730,319.82, contrasting with a comprehensive loss of CNY 30,237,908.44 in the previous period[96]. - Net profit for the current period was ¥628,028,719.26, a turnaround from a net loss of ¥92,957,268.38 in the previous period[107]. - The company reported a profit margin of approximately 16.7% for the current period, compared to a negative margin in the previous period[107]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥7,696,284,318.32, a decrease of 1.08% compared to the previous year[8]. - The total liabilities decreased to ¥3,919,972,483.25 from ¥4,601,519,978.02, reflecting a reduction of about 14.8%[52]. - The total equity attributable to the parent company increased to ¥3,771,237,126.65 from ¥3,172,991,646.22, representing an increase of approximately 18.8%[52]. - The company's cash and cash equivalents decreased to ¥164,883,762.96 from ¥707,129,896.57, a decline of about 76.7%[53]. - The total current liabilities decreased to ¥2,937,394,751.55 from ¥3,625,306,782.00, showing a reduction of approximately 19.0%[52]. - The company's long-term equity investments decreased by 89.75% to ¥49,864,083.17 due to equity reductions[19]. - The company's short-term borrowings increased by 65.33% to ¥1,275,500,000.00, reflecting a rise in current loans[19]. - The company reported a total of CNY 30,470,000.00 in entrusted financial management, with no overdue amounts[35]. Cash Flow - Net cash flow from operating activities was ¥168,557,490.25, reflecting a remarkable increase of 2,481.56% year-on-year[8]. - The net cash flow from operating activities improved by 428.41% to ¥374,643,683.02, driven by the phosphochemical business data[23]. - Cash inflow from operating activities reached 3,386,101,698.99 CNY, significantly up from 579,709,306.29 CNY in the previous period[151]. - The net cash flow from investment activities was negative 799,441,395.48 CNY, a decline from a positive 169,175,007.75 CNY in the previous period[155]. - Cash inflow from financing activities was 1,113,551,971.74 CNY, with cash outflow totaling 1,130,501,374.93 CNY, resulting in a net cash flow of negative 16,949,403.19 CNY[155]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 76,201[12]. - The top ten shareholders held a total of 238,665,955 shares, accounting for 17.32% of the total shares[12]. - The company has received approval for a non-public issuance of A-shares, pending shareholder approval[26]. Business Operations - The company plans to continue expanding its phosphochemical business and is actively pursuing new investment opportunities[24]. - The company reported a significant increase in sales expenses, which rose to ¥189,971,012.91 from ¥8,383,169.37, indicating a growth of approximately 2165.5%[104]. - Research and development expenses totaled CNY 14,814,312.21, up from CNY 1,218,726.99 in the previous period, indicating increased investment in innovation[89]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[106].